Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Of 203 patients who underwent cardiac transplantation and were given long-term treatment with cyclosporine and 0.3 mg/kg per day prednisone, 123 were studied prospectively for at least 6 months and 46 for up to 2 years to evaluate the effects on lumbar bone mineral density (BMD) and calcium metabolism of a combined therapy with calcium, calcidiol and disodium monofluorophosphate (MFP). The population was arbitrarily assigned to one of two groups. Group I consisted of patients who had a lumbar spine BMDZ score above −1.5 SD as compared with an age-and sex-matched population and no vertebral fractures. They received daily 1 g elemental calcium and 25 µg (1000 IU) calcidiol. Group II consisted of patients who received daily the same doses of calcium and calcidiol combined with 200 mg MFP, and was divided into two subgroups: (a) osteopenic subjects who had a lumbar spine BMD Z score below −1.5 SD without vertebral fractures and (b) osteoporotic subjects with vertebral fractures. If serum creatinine was higher than 140 µmol/l the daily dose of MFP was tapered to 100 mg. Fifty-four and 27 patients from group I and 38 and 19 patients from group II were followed respectively for 12 and 24 months. In both groups serum parathyroid hormone levels were significantly reduced from the twelfth month in parallel with a significant increase in serum 25-OHD levels. No decline in lumbar BMD occurred in non-osteopenic and non-osteoporotic patients (group I) who received the calcium and calcidiol supplement. In group II, where MFP was added, a significant and linear increase in lumbar BMD was observed. The average increase reached 12.5% after 12 months and 29.5% after 24 months (p<0.0001). The magnitude of the response was similar to the response previously reported in patients suffering from vertebral fractures due to postmenopausal osteoporosis and treated with the same daily dose of MFP. Because osteoporosis and fractures are not rare in patients after cardiac transplantation, these pilot results may be useful for further prevention and treatment trials of bone loss in this condition.
- Katz IA, Epstein S. Posttransplantation bone disease. J Bone Miner Res 1992;7:123–6.
- Meunier PJ, Terreaux F, Dureau G, Joly R, Beaume T. Bone status after cardiac transplantation: effects of fluoride, calcium and vitamin D. J Bone Miner Res 1989; 4 Suppl 1: abstract 768.
- Muchmore JS, Cooper DKC, Ye Y, Schlegel VT, Zuhdi N. Loss of vertebral bone density in heart transplant patients. Transplant Proc 1991;23:1184–5.
- Jackson RD, Springer C, Starling R, Myerowitz PD. Bone loss following cardiac transplantation. J Bone Miner Res 1991; 6 Suppl 1:303.
- Meunier PJ, Briancon D, Chavassieux P, et al. Treatment with fluoride: bone histomorphometric findings. In: Christiansen C, Johansen JS, Riis BJ (eds) Osteoporosis 1987. Copenhagen: Osteopress, 1987: 824–8.
- Leblanc AD, Schneider VS, Harlan JE, Engelbretson DA, Krebs JM. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 1990;5:843–50.
- Stewart PJ, Green OC, Stern PH. Cyclosporine A inhibits calcemic hormone-induced bone resportion in vitro. J Bone Miner Res 1986;1:285–91.
- Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988;123:2571–7.
- Orcel P, Bielakoff J, Modrowski D, Miravet L, de Vernejoul MC. Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J Bone Miner Res 1989;4:387–91.
- Kelly PJ, Sambrook PN, Eisman JA. Potential protection by cyclosporin against glucocorticoid effects on bone. Lancet 1989;2:1388.
- Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, Esselinckx W, Stass P. The effect of small equivalent doses of deflazacort and prednisone on the bone mineral content in male patients with rheumatoid arthritis. J Bone Miner Res 1986; 1 Suppl 1: 172.
- Olgaard K, Storm T, Wowern N, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versud deflazacort. Calcif Tissue Int 1992;50:490–7.
- Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983;35:410–7.
- Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137–41.
- Kotowicz MA, Hall S, Hunder GG, Cedel SL, Mann KG, Riggs BL. Relationship of glucocorticoid dosage to serum bone-Glaprotein concentration in patients with rheumatologic disorders. Arthritis Rheum 1990;33:1487–92.
- Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352–64.
- Paz-Pacheco E, El-Hajj Fuleihan, LeBoff MS. Intact PTH levels are not elevated in steroid-treated osteoporosis. J Bone Miner Res 1991; 6 Suppl 1: abstract 373.
- Bressot C, Meunier PJ, Chapuy MC, et al. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979;1:303–11.
- Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25 hydroxyvitamin D administration. J Clin Invest 1979;64:655–65.
- Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 1983;227:320–32.
- Rico H, Cabranes JA, Hernandez ER, Barabash A, Romero P. Reversion of the steroid-induced decrease of serum osteocalcin with sodium fluoride. Clin Rheum 1991;10:10–12.
- Rickers H, Deding A, Christiansen C, Rodbro P, Waestroft J. Corticosteroid-induced osteopenia and vitamin D metabolism: effect of vitamin D, calcium phosphate and sodium fluoride administration. Clin Endocrinol 1982; 16:409–15.
- Bayley TA, Muller C, Harrison J, et al. The long-term treatment of steroid osteoporosis with fluoride. J Bone Miner Res 1990; 5 Suppl 1:157–61.
- Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements. J Bone Miner Res 1990; 5 Suppl 1:5–26.
- Greenwald M, Brandli D, Golde G, Spectator S, Silverman S. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporosis Int 1992;2:303–4.
- Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res 1990; 5 Suppl 1:143–7.
- Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate
Volume 3, Issue 6 , pp 322-329
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Cardiac transplantation
- Glucocorticoid-induced osteoporosis
- Parathyroid hormone
- Vitamin D
- Industry Sectors
- Author Affiliations
- 1. INSERM Unit 234 and Department of Rheumatology and Bone Diseases, Hôpital Edouard Herriot, Lyon, France
- 2. Department of Cardiac Surgery and Transplantation, Hôpital Cardiovasculaire et Pneumologique Louis Pradel, Lyon, France